30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

The Lancet Oncology

Volumn 17, Issue 9, 2016, Pages 1203-1216

  Wallington, Michael ^a   Saxon, Emma B ^b   Bomb, Martine ^a   Smittenaar, Rebecca ^b   Wickenden, Matthew ^b   McPhail, Sean ^a   Rashbass, Jem ^a   Chao, David ^c   Dewar, John ^d   Talbot, Denis ^e   Peake, Michael ^a,f   Perren, Timothy ^g   Wilson, Charles ^h   Dodwell, David ^g  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL DECISION MAKING; CONTROLLED STUDY; ENGLAND; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MORTALITY RISK; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; PATIENT CARE; POPULATION RESEARCH; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; AGED; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TIME FACTOR;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; ENGLAND; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 84994539749     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30383-7     Document Type: Article

References (32)

1. 1 Chabner, BA, Roberts, TG, Chemotherapy and the war on cancer. Nat Rev Cancer 5 (2005), 65–72.
2. 2 Morgan, G, Ward, R, Barton, M, The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol 16 (2004), 549–560.
3. 3 Fossati, R, Confalonieri, C, Torri, V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16 (1998), 3439–3460.
4. 4 Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995), 899–909.
5. 5 Mort, D, Lansdown, M, Smith, N, Protopapa, K, Mason, M, Systemic Anti-Cancer Therapy: For better, for worse? National Confidential Enquiry into Patient Outcome and Death. [Online]. Available at: http://www.ncepod.org.uk/2008report3/Downloads/SACT_report.pdf (accessed March 21, 2016).
6. 6 Khoja, L, McGurk, A, O'Hara, C, Chow, S, Hasan, J, Mortality within 30 days following SACT, a review of all cases over a 4 year period in a tertiary cancer centre. Eur J Cancer 51 (2015), 233–240.
7. 7 O'Brien, ME, Borthwick, A, Rigg, A, et al. Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. Br J Cancer 95 (2006), 1632–1636.
8. 8 Yoong, J, Seah, JA, Hamilton, K, Teo, LN, Chong, G, Mortality within 30 days of receiving SACT at a regional oncology unit: what have we learned?. Asia Pac J Clin Oncol 8 (2012), 325–329.
9. 9 Arriagada, R, Bergman, B, Dunant, A, Le Chevalier, T, Pignon, JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004), 351–360.
10. 10 Ellis, P, Barrett-Lee, P, Johnson, L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373 (2009), 1681–1692.
11. 11 STROBE statement. Available at: http://www.strobe-statement.org/index.php?id=strobe-home (accessed May 11, 2016).
12. 12 Central Office of Information. NHS Cancer Reform Strategy [Online]. http://webarchive.nationalarchives.gov.uk/20130107105354/ http:/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_081007.pdf (accessed March 23, 2016).
13. 13 Health and Social Care Information Centre (HSCIC). Data Set: Systemic Anti-Cancer Therapy dataset. http://www.datadictionary.nhs.uk/data_dictionary/messages/clinical_data_sets/data_sets/systemic_anti-cancer_therapy_data_set_fr.asp?shownav=1 (accessed May 11, 2016).
14. 14 National Cancer Registration and Analysis Service. Completeness of the national Systemic Anti-Cancer Therapy data set compared with the Cancer Waiting Times data set [Online]. Available at: http://www.ncin.org.uk/publications/data_briefings/sact_cwt (accessed March 23, 2016).
15. 15 Social Disadvantage Research Centre, University of Oxford. The English indices of deprivation. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/6871/1871208.pdf, 2010 (accessed March 23, 2016).
16. 16 Sterne, JAC, White, IR, Carlin, JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ, 338, 2009, b2393.
17. 17 Harrell, FE Jr, Lee, KL, Mark, DB, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996), 361–387.
18. 18 Concato, J, Peduzzi, P, Holford, TR, Feinstein, AR, Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 48 (1995), 1495–1501.
19. 19 Peduzzi, P, Concato, J, Feinstein, AR, Holford, TR, Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48 (1995), 1503–1510.
20. 20 Oken, MM, Creech, RH, Tormey, DC, Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982), 649–655.
21. 21 Department of Health. Improving outcomes: a strategy for cancer 2011 [Online]. available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213785/dh_123394.pdf (accessed March 23, 2016).
22. 22 Radford, J, Ryder, D, Dodwell, D, Anderson, H, Thatcher, N, Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 29A (1992), 81–86.
23. 23 Hsu, CL, Chen, KY, Shih, JY, et al. Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors. BMC Cancer, 12, 2012, 241.
24. 24 Greenman, CG, Jagielski, CH, Griggs, JJ, Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice. Cancer 112 (2008), 2159–2165.
25. 25 Griggs, JJ, Mangu, PB, Anderson, H, Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 30 (2012), 1–10.
26. 26 Ross, PJ, Ashley, S, Norton, A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. Br J Cancer 90 (2004), 1905–1911.
27. 27 Chan, DS, Vieira, AR, Aune, D, Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25 (2014), 1901–1914.
28. 28 Heon, S, Johnson, BE, Adjuvant chemotherapy for surgically resected non-small cell lung cancer. J Thorac Cardiovasc Surg 144 (2012), 39–42.
29. 29 NHS Cancer Data. Incidence (base numbers). https://www.cancerdata.nhs.uk/incidence/base_numbers (accessed March 23, 2016).
30. 30 Prigerson, HG, Bao, Y, Shah, MA, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 1 (2015), 778–784.
31. 31 The National Council for Palliative Care. Getting serious about prevention: enabling people to stay out of hospital at the end of life. http://www.ncpc.org.uk/sites/default/files/Getting%20Serious_WEB.pdf (accessed March 23, 2016).
32. 32 Slevin, ML, Stubbs, L, Plant, HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300 (1990), 1458–1460.